Brainstorm Cell Therapeutics (BCLI) Competitors $0.60 -0.05 (-8.00%) As of 08/14/2025 03:33 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI vs. BDRX, RNTX, NNVC, TENX, JATT, BTAI, FBLG, MIRA, NAII, and CVKDShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Biodexa Pharmaceuticals (BDRX), Rein Therapeutics (RNTX), NanoViricides (NNVC), Tenax Therapeutics (TENX), JATT Acquisition (JATT), BioXcel Therapeutics (BTAI), FibroBiologics (FBLG), MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Its Competitors Biodexa Pharmaceuticals Rein Therapeutics NanoViricides Tenax Therapeutics JATT Acquisition BioXcel Therapeutics FibroBiologics MIRA Pharmaceuticals Natural Alternatives International Cadrenal Therapeutics Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Do analysts rate BCLI or BDRX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BCLI or BDRX more profitable? Company Net Margins Return on Equity Return on Assets Brainstorm Cell TherapeuticsN/A N/A -519.50% Biodexa Pharmaceuticals N/A N/A N/A Which has better earnings & valuation, BCLI or BDRX? Biodexa Pharmaceuticals has higher revenue and earnings than Brainstorm Cell Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBrainstorm Cell TherapeuticsN/AN/A-$11.62M-$3.36-0.18Biodexa Pharmaceuticals$470K54.67-$7.32MN/AN/A Do insiders & institutionals believe in BCLI or BDRX? 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to BCLI or BDRX? In the previous week, Brainstorm Cell Therapeutics had 5 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 7 mentions for Brainstorm Cell Therapeutics and 2 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.43 beat Brainstorm Cell Therapeutics' score of 0.25 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Brainstorm Cell Therapeutics Neutral Biodexa Pharmaceuticals Positive Which has more volatility and risk, BCLI or BDRX? Brainstorm Cell Therapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. SummaryBiodexa Pharmaceuticals beats Brainstorm Cell Therapeutics on 6 of the 9 factors compared between the two stocks. Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.24M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-0.1820.4930.2925.74Price / SalesN/A356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book-0.448.608.826.15Net Income-$11.62M-$54.65M$3.25B$265.06M7 Day Performance4.07%5.86%3.70%2.60%1 Month Performance-49.71%8.86%5.84%2.83%1 Year Performance-87.15%13.33%29.92%25.58% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics2.4351 of 5 stars$0.60-8.0%N/A-86.8%$7.24MN/A-0.1840News CoverageShort Interest ↓BDRXBiodexa Pharmaceuticals1.0231 of 5 stars$6.89-3.4%N/AN/A$26.06M$470K0.0020Positive NewsShort Interest ↓RNTXRein TherapeuticsN/A$1.16+4.5%N/AN/A$25.58MN/A-0.419News CoverageEarnings ReportNNVCNanoViricides0.3136 of 5 stars$1.54-2.5%N/A-23.0%$24.75MN/A-2.1420TENXTenax Therapeutics1.9721 of 5 stars$5.85-1.0%$17.50+199.1%+50.6%$24.52MN/A-2.369News CoverageEarnings ReportAnalyst ForecastJATTJATT AcquisitionN/A$1.42-4.1%N/A-51.7%$24.50MN/A0.003Gap UpHigh Trading VolumeBTAIBioXcel Therapeutics4.4611 of 5 stars$6.40+58.4%$49.25+669.5%-56.3%$24.47M$2.27M-0.4790Earnings ReportShort Interest ↓Gap DownHigh Trading VolumeFBLGFibroBiologics3.2231 of 5 stars$0.55-4.8%$13.00+2,243.6%-65.8%$24.40MN/A-1.5410Short Interest ↑Gap DownMIRAMIRA Pharmaceuticals3.2206 of 5 stars$1.42+2.9%$17.00+1,097.2%-23.8%$23.35MN/A-2.782Earnings ReportShort Interest ↓NAIINatural Alternatives International1.54 of 5 stars$3.70-0.1%N/A-27.6%$22.89M$113.80M-2.66290Gap DownHigh Trading VolumeCVKDCadrenal Therapeutics2.9055 of 5 stars$10.94-1.9%$32.00+192.5%N/A$22.82MN/A-1.184Earnings ReportShort Interest ↑Analyst RevisionGap Up Related Companies and Tools Related Companies BDRX Competitors RNTX Competitors NNVC Competitors TENX Competitors JATT Competitors BTAI Competitors FBLG Competitors MIRA Competitors NAII Competitors CVKD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCLI) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access